Thank you, Cabinet Secretary. Your decision to enable access to Kadcyla is a welcome development, and I would like to pay tribute to all the campaigners throughout the UK who have fought for so long to have access to this life-extending drug. This targeted therapy is vital for those who have certain HER2-positive breast cancers, but it originally came with a very high financial cost, and we all recognise that it is incumbent upon the National Institute for Health and Care Excellence to ensure that taxpayers’ investment in modern drug treatments has a measure of cost-effectiveness. Of course, it’s not just about the money, as those who use this drug and want more time with their loved ones will attest.

My understanding is that one of the reasons that Kadcyla was able to gain NICE approval was because of the revised methodology used to compare its efficacy against different combinations of treatment. Are you able to give an insight into the methodology process used by NICE? Is the principle behind the revised methodology process for green-lighting Kadcyla able to be used in connection with other drugs that are currently not available? Orkambi, for example, comes to mind. I appreciate that you will not be able to disclose the detail of the commercial agreement between the Welsh Government and Roche, however I would be interested to know if it is the same deal as the one NHS England secured. Finally, what lessons are we able to take from this in order to exploit new drug therapies to help our sickest people whilst preserving an appropriate margin window for developers and manufacturers and, at the same time, ensuring that taxpayers’ money is spent wisely?